Both the up-modulation of surface DR4 by TACE inhibition and the potentiation of the DR-mediated pro-apoptotic signaling are suggested to be required for full restoration of the susceptibility of MM cells to TRAIL-mediated immunotherapy. This evidence concerns the gene ADAM17 and Miyoshi myopathy.